Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.

What was studied

This review looked at antibodies that form against biologic drugs. The disease was psoriatic arthritis. It covered adults who took these drugs. The team searched several databases. They included 28 studies. Of these, 19 were randomized trials and 9 were observational.

What they found

How often antibodies appeared varied widely between drugs. It also varied between studies of the same drug. Tests differed, so rates could not be compared directly. Rates were highest for adalimumab and infliximab. Some drugs had very low or no antibodies. For TNF inhibitors, antibodies went with lower drug levels and weaker response. Using methotrexate went with fewer antibodies. Side effects tied to this were rare. Data for other drug types were thin.

What it means for patients

The authors say antibodies seem most relevant for TNF inhibitors. Evidence for other drug classes is limited. More work is needed. They call for studies that use the same methods and follow patients forward.

Why it is not certain yet

Test methods differed, so the studies are hard to compare. Data on some drug classes were limited or lacking. Evidence on side effects was not enough. A review can only be as good as the studies in it.

Source

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.

We restate facts from the source record in our own words. The original wording belongs to its publisher.